Novartis taps new U.S. pharma chief

The musical chairs game in Novartis' top management ranks is continuing as new pharma chief Joe Jimenez revamps the ranks. The Swiss drugmaker has appointed Ludwig Hantson to top its U.S. pharmaceuticals business. Hantson takes over for Alex Gorsky, whose departure was announced in February; previously, Hantson ran Novartis' European pharma business.

Jiminez, Hantson's boss, said his experience with Europe's penny-pinching healthcare systems should help him deal with increasingly cost-conscious insurers and government payers in the U.S.

Meanwhile, Paulo Costa, president and CEO of Novartis, which oversees all Novartis Group companies in North America, will retire June 30; he'll be replaced by Gary Rosenthal, currently CFO and interim chief of the U.S. pharma biz.

- read the Wall Street Journal story
- see the article in the Star-Ledger
- check out the item at Medical Marketing & Media

ALSO: PDI, which provides contract sales teams to pharma companies, said it's made a deal with Novartis to sell an unnamed product in the U.S.; the arrangement will involve 100 contract sales reps. Report

Related Articles:
Novartis discovery chief departs in management shakeup. Novartis report
U.S. CEO exits Novartis. Novartis report
CEO: Novartis plans big restructuring. Novartis report
Lagging sales spur Novartis layoffs. Novartis report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.